Physician profile
Molly Rolen
NPI 1811659394
$1,505.61
in general payments reported to CMS, 2019-2025
21 companies · $596 in 2025
The $596 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $245 · 2024: $507 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $306.34 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $159.95 | 2022-2025 | |
| Theratechnologies INC. | $150.24 | 2023-2025 | Egrifta, Trogarzo |
| Otsuka America Pharmaceutical, INC. | $124.20 | 2023-2025 | Rexulti |
| Allergan, INC. | $118.53 | 2022 | |
| Lilly USA, LLC | $80.67 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $76.57 | 2022-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $74.15 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $58.58 | 2024-2025 | Pifeltro, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $52.26 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $43.21 | 2025 | |
| Viiv Healthcare Company | $41.87 | 2025 | Cabenuva, Dovato |
| Lundbeck LLC | $40.77 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.37 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $32.79 | 2023 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $24.80 | 2025 | Nuplazid |
| Amgen INC. | $21.30 | 2024 | Otezla, Repatha |
| Pfizer INC. | $19.50 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.96 | 2024 | Zoryve |
| Seqirus USA INC | $15.18 | 2024 | Fluad, Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.37 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Rolen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.